A Phase II, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy.

Trial Profile

A Phase II, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2013

At a glance

  • Drugs CH 4051 (Primary) ; Folic acid; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms MOTION
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2012 Additional locations (Argentina, Mexico, Poland) added and company (Hospira) added as reported by European Clinical Trials Database record.
    • 31 May 2012 Primary endpoints 'American-College-of-Rheumatology-response-criteria' (hybrid score) and 'American-College-of-Rheumatology-20%-response-criteria' have not been met according to a Chelsea Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top